FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, NASDAQ: GTCB) has appointed Evelyne Nguyen, Jean-François Prost M.D., Bertrand Merot, Ph.D., and William Heiden as directors. These directors were nominated by LFB Biotechnologies in accordance with its right under GTC’s funding agreements to appoint a number of directors commensurate with LFB’s ownership of GTC. To accommodate LFB’s plan not to increase the size of the GTC Board, Robert Baldridge, Kenneth Bauer M.D., Mary Ann Gray, Ph.D., and Marvin Miller resigned as directors.
